PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)
← catalyst calendarNCT07106970 · readout in 498 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
640estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-28 | actual | When the study began enrolling |
| Primary completion | 2027-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Persistent Atrial Fibrillation
Interventions
- Procedure: Linear ablation
- Procedure: PVI alone
Primary outcomes
what the primary-completion date above is the date OFPrimary Effectiveness Endpoint with Treatment Success.
measured Completion of treatment 360 days compared with the baseline
Primary Safety Endpoint with Safety events related to AF catheter ablation.
measured Completion of treatment 360 days compared with the baseline
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed